
Giuseppe Curigliano
Articles
-
1 month ago |
nature.com | Avantika Gupta |Fresia Pareja |David Brown |Yingjie Zhu |Juan Blanco-Heredia |Bojana Stefanovska | +11 more
AbstractAcquired genetic alterations drive resistance to endocrine and targeted therapies in metastatic breast cancer; however, the underlying processes engendering these alterations are largely uncharacterized. To identify the underlying mutational processes, we utilized a clinically annotated cohort of 3,880 patient samples with tumor-normal sequencing.
-
Jan 16, 2025 |
reference.medscape.com | Giuseppe Curigliano
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. The World Health Organization (WHO) released updated brain tumor classification guidelines in 2021, which built upon the traditional histologic classification system that has defined brain tumor staging.
-
Jan 16, 2025 |
reference.medscape.com | Giuseppe Curigliano
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Isocitrate dehydrogenase (IDH) is an important biomarker in brain cancer and an essential diagnostic criterion in the current World Health Organization (WHO) tumor classification system.
-
Dec 5, 2024 |
ejcancer.com | Giuseppe Curigliano
Keywordsendocrine therapymetastatic breast canceroligoprogressionstereotactic radiotherapyGet full text accessLog in, subscribe or purchase for full access. References1. Siegel, R.L. ∙ Giaquinto, A.N. ∙ Jemal, A. Cancer statistics, 2024CA Cancer J Clin. 2024; 74:12-492. Gennari, A. ∙ André, F. ∙ Barrios, C.H. ... ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology. 2021; 32:1475-14953. Valenza, C. ∙ Trapani, D. ∙ Bidard, F.-C.
-
Jul 18, 2024 |
onclive.com | Giuseppe Curigliano
CommentaryVideoJuly 18, 2024Author(s):Giuseppe Curigliano, MD, PhD, discusses the implications of treatment with T-DXd in HR+, HER2-low or HER2-ultralow metastatic breast cancer.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →